Carcinoembryonic antigen (CEA) is also a valuable target for adoptive cell therapy, as this glycoprotein family is expressed in nearly 75% of pancreatic cancers, and its upregulation is correlated with KRAS-driven metastatic CRC (110–112). This evidence concerns the gene KRAS and familial pancreatic carcinoma.